Cüneyt Türkmen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cüneyt Türkmen has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Ayşegul Gormez
Department of Radiology, Yeditepe University Hospitals, Kosuyolu, Istanbul, 34718, Turkey
3 shared publications - Osman Melih Topcuoglu
Department of Radiology, Yeditepe University Hospitals, Kosuyolu, Istanbul, 34718, Turkey.
3 shared publications - Bayram Demir
Faculty of Science, Department of Physics, Istanbul University, 34134 Istanbul, Türkiye
1 shared publication - Betul Uzunoglu
Radiology Resident, Yeditepe University Hospitals , Istanbul
1 shared publication Bilal Kovan
1 shared publication- Bilal Kovan
Istanbul University, Istanbul Faculty of Medicine
1 shared publication
Latest Publications
- Open Access
- 22 May 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
Tumor absorbed dose and outcomes after Y-90 glass radioembolization for colorectal liver metastases: does dose escalation improve survival in real-world practice?
Purpose: To assess the dose-response and dose-survival outcomes of yttrium-90 (Y90) transarterial radioembolization (TARE) using Therasphere microspheres in patients with colorectal cancer liver metastases (CRCLM). Material and methods: Between May 2014 and December 2024, patients with chemorefractory CRCLM who underwent Y90 TARE using glass microspheres were retrospectively included. Patients were divided into two groups according to tumour absorbed dose (TAD): TAD<189 Gy (group 1) and TAD ≥189 Gy (group 2). The primary outcomes were overall survival (OS) and hepatic progression-free survival (hPFS). The secondary outcome was the objective response rate (ORR). Results: A total of seventy-eight patients with a mean age of 69.9±11.2 years (range 41 to 91 years) were included. The median tumor dose and the median OS were 171.5 Gy (IQR; 147-200 Gy) and 8.9 months ( IQR; 5-14 months), respectively. The median TAD for groups 1 (n=46) and 2 (n=32) was 150 Gy (IQR; 122-166 Gy) and 202 Gy (IQR; 195-232 Gy), respectively. The median OS and hPFS for group 1 versus group 2 were 9.4 months (IQR; 6.7–17.7 months) and 5.2 months (IQR; 4-6.7 months) versus 7.1 months (IQR; 5–10.7 months) and 5.5 months (IQR; 4.2-6.7 months), respectively and were not significantly different (p = .107 and p = .663, respectively). The ORR did not differ significantly between the two groups (p = .943). Conclusion: In a real-world population of heavily pretreated patients with CRCLM, escalation of TAD beyond 189 Gy did not translate into improved survival, highlighting the dominant impact of advanced disease burden and extrahepatic progression.
- 22 May 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
Open AccessTumor absorbed dose and outcomes after Y-90 glass radioembolization for colorectal liver metastases: does dose escalation improve survival in real-world practice?
Purpose: To assess the dose-response and dose-survival outcomes of yttrium-90 (Y90) transarterial radioembolization (TARE) using Therasphere microspheres in patients with colorectal cancer liver metastases (CRCLM). Material and methods: Between May 2014 and December 2024, patients with chemorefractory CRCLM who underwent Y90 TARE using glass microspheres were retrospectively included. Patients were divided into two groups according to tumour absorbed dose (TAD): TAD<189 Gy (group 1) and TAD ≥189 Gy (group 2). The primary outcomes were overall survival (OS) and hepatic progression-free survival (hPFS). The secondary outcome was the objective response rate (ORR). Results: A total of seventy-eight patients with a mean age of 69.9±11.2 years (range 41 to 91 years) were included. The median tumor dose and the median OS were 171.5 Gy (IQR; 147-200 Gy) and 8.9 months ( IQR; 5-14 months), respectively. The median TAD for groups 1 (n=46) and 2 (n=32) was 150 Gy (IQR; 122-166 Gy) and 202 Gy (IQR; 195-232 Gy), respectively. The median OS and hPFS for group 1 versus group 2 were 9.4 months (IQR; 6.7–17.7 months) and 5.2 months (IQR; 4-6.7 months) versus 7.1 months (IQR; 5–10.7 months) and 5.5 months (IQR; 4.2-6.7 months), respectively and were not significantly different (p = .107 and p = .663, respectively). The ORR did not differ significantly between the two groups (p = .943). Conclusion: In a real-world population of heavily pretreated patients with CRCLM, escalation of TAD beyond 189 Gy did not translate into improved survival, highlighting the dominant impact of advanced disease burden and extrahepatic progression.
- Open Access
- 28 January 2026
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 44 (6) , 1062-1070
18F-FDG PET radiomics model for predicting TARE response in patients with colorectal cancer liver metastases
Purpose: Predicting treatment response in patients with colorectal cancer liver metastases (CRCLM) who have undergone transarterial radioembolization (TARE) based on pre-procedural fluorine-18-fluoro-deoxy glucose positron emission tomography ( 18 F-FDG PET) radiomics and clinical information. Materials and methods: Patients with CRCLM who underwent TARE, between March 2015 and May 2025, were consecutively included. Largest tumors were segmented semiautomatically using pre-procedural 18 F-FDG PET images. Radiomics features were extracted, clinical information were collected. Two datasets were created comprising radiomics-only and clinico-radiomic features. Datasets were divided 60:40 for training and testing. Top 5 features were selected based on feature importances. Random Forest, Extreme Gradient Boosting, Logistic Regression models were trained. Test-set area under the curves (AUCs) for predicting post-treatment target lesion local progression were calculated and compared using DeLong’s test. Sensitivity, specificity, accuracy and F1 scores were calculated at the optimal cut-offs. Results: Seventy-four patients out of 96 patients were included. Top five selected features in the radiomics-only dataset were Coarseness, IMC1, Zone Entropy, Size-Zone Non-Uniformity, and Strength. In the clinico-radiomic dataset, AST and ALT levels were substituted among the top five features. Radiomics-only features demonstrated AUCs ranging from 0.90 (95% CI 0.71–1) to 0.81 (95% CI 0.51–1) in the test-set while clinico-radiomics dataset AUCs varied between 0.88 (95% CI 0.51–1) and 0.84 (0.62–1). Conclusion: 18 F-FDG PET radiomics based models can predict the local response to TARE in patients with CRCLM, in this series.
- 28 January 2026
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 44 (6) , 1062-1070
Open Access18F-FDG PET radiomics model for predicting TARE response in patients with colorectal cancer liver metastases
Purpose: Predicting treatment response in patients with colorectal cancer liver metastases (CRCLM) who have undergone transarterial radioembolization (TARE) based on pre-procedural fluorine-18-fluoro-deoxy glucose positron emission tomography ( 18 F-FDG PET) radiomics and clinical information. Materials and methods: Patients with CRCLM who underwent TARE, between March 2015 and May 2025, were consecutively included. Largest tumors were segmented semiautomatically using pre-procedural 18 F-FDG PET images. Radiomics features were extracted, clinical information were collected. Two datasets were created comprising radiomics-only and clinico-radiomic features. Datasets were divided 60:40 for training and testing. Top 5 features were selected based on feature importances. Random Forest, Extreme Gradient Boosting, Logistic Regression models were trained. Test-set area under the curves (AUCs) for predicting post-treatment target lesion local progression were calculated and compared using DeLong’s test. Sensitivity, specificity, accuracy and F1 scores were calculated at the optimal cut-offs. Results: Seventy-four patients out of 96 patients were included. Top five selected features in the radiomics-only dataset were Coarseness, IMC1, Zone Entropy, Size-Zone Non-Uniformity, and Strength. In the clinico-radiomic dataset, AST and ALT levels were substituted among the top five features. Radiomics-only features demonstrated AUCs ranging from 0.90 (95% CI 0.71–1) to 0.81 (95% CI 0.51–1) in the test-set while clinico-radiomics dataset AUCs varied between 0.88 (95% CI 0.51–1) and 0.84 (0.62–1). Conclusion: 18 F-FDG PET radiomics based models can predict the local response to TARE in patients with CRCLM, in this series.
- Open Access
- 10 May 2024
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 97 (1159) , 1255-1260
Are survival outcomes dependent on the tumour dose threshold of 139 Gy in patients with chemorefractory metastatic colorectal cancer treated with yttrium-90 radioembolization using glass particles? A real-world single-centre study
To compare the survival and objective response rate (ORR) of the patients receiving estimated tumour absorbed dose (ETAD) P = .181 and P = .366, respectively). ORR did not show significant difference between the groups (P = .432). In real-world practice, no significant difference was found in OS, hPFS, and ORR between patients who received ETAD <140 Gy versus ETAD ≥140 Gy in patients with CRCLM, in this series. This study demonstrated that increased tumour absorbed doses in radioembolization may not provide additional significant advantage for OS and hPFS for patients with CRCLM.
- 10 May 2024
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 97 (1159) , 1255-1260
Open AccessAre survival outcomes dependent on the tumour dose threshold of 139 Gy in patients with chemorefractory metastatic colorectal cancer treated with yttrium-90 radioembolization using glass particles? A real-world single-centre study
To compare the survival and objective response rate (ORR) of the patients receiving estimated tumour absorbed dose (ETAD) P = .181 and P = .366, respectively). ORR did not show significant difference between the groups (P = .432). In real-world practice, no significant difference was found in OS, hPFS, and ORR between patients who received ETAD <140 Gy versus ETAD ≥140 Gy in patients with CRCLM, in this series. This study demonstrated that increased tumour absorbed doses in radioembolization may not provide additional significant advantage for OS and hPFS for patients with CRCLM.
- Open Access
- 29 December 2023
- Published by INESEG Yayincilik in Middle East Journal of Science
- Vol. 9 (2) , 57-66
INVESTIGATION OF CENTERING PROBLEM IN THE CADMIUM ZINC TELLURIDE (CZT) CARDIAC CAMERA
Introduction: Cadmium Zinc Telluride (CZT) Cardiac Cameras are a special SPECT cameras with solid state cadmium zinc telluride detectors. This diagnostic method applied in the evaluation of coronary artery disease is well designed for myocardial perfusion scintigraphy. Aim: CZT cardiac cameras have limited detector area. In patients who are morbidly obese or whose heart is not in its normal location in the body, the center of the heart and the isocenter of the device do not coincide. It is aim to investigate how these conditions affect the imaging performance of the CZT cardiac camera. Methods: A homogeneous and spherical ball with a diameter of 4 cm was used for the research. To be able to measure away from the center a wooden phantom with 8 cavities and a total length of 32 cm was designed. The center as reference point has been determined by matching the center of the device with the center of the sphere. For the next imaging, the image were taken by placing the spherical ball in the other cavities, respectively, without changing the center. Results: According to the results obtained, farther from the center, deviations from sphericity and differences in dose distribution were observed. Counts decreased by 1.5% in the 2nd position and 16% in the 3rd position relative to the center in the X-axis. A disaster area has been formed and the image area has been exited from the 4th imaging. Conclusion: It is very important to center the patient as much as possible, otherwise the doctor will misdiagnose.
- 29 December 2023
- Published by INESEG Yayincilik in Middle East Journal of Science
- Vol. 9 (2) , 57-66
Open AccessINVESTIGATION OF CENTERING PROBLEM IN THE CADMIUM ZINC TELLURIDE (CZT) CARDIAC CAMERA
Introduction: Cadmium Zinc Telluride (CZT) Cardiac Cameras are a special SPECT cameras with solid state cadmium zinc telluride detectors. This diagnostic method applied in the evaluation of coronary artery disease is well designed for myocardial perfusion scintigraphy. Aim: CZT cardiac cameras have limited detector area. In patients who are morbidly obese or whose heart is not in its normal location in the body, the center of the heart and the isocenter of the device do not coincide. It is aim to investigate how these conditions affect the imaging performance of the CZT cardiac camera. Methods: A homogeneous and spherical ball with a diameter of 4 cm was used for the research. To be able to measure away from the center a wooden phantom with 8 cavities and a total length of 32 cm was designed. The center as reference point has been determined by matching the center of the device with the center of the sphere. For the next imaging, the image were taken by placing the spherical ball in the other cavities, respectively, without changing the center. Results: According to the results obtained, farther from the center, deviations from sphericity and differences in dose distribution were observed. Counts decreased by 1.5% in the 2nd position and 16% in the 3rd position relative to the center in the X-axis. A disaster area has been formed and the image area has been exited from the 4th imaging. Conclusion: It is very important to center the patient as much as possible, otherwise the doctor will misdiagnose.
- 19 November 2021
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 27 (6) , 732-739
The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey
Clinical studies conducted in different geographic regions using different methods to compare transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) have demonstrated discordant results. Meta-analyses in this field indicate comparable overall survival (OS) with TACE and TARE, while reporting a longer time to progression and a higher downstaging effect with TARE treatment. In terms of isolated procedure costs, treatment with TARE is 2 to 3 times more, and in some countries even more, expensive than TACE. However, relevant literature indicates that TARE is more advantageous compared to TACE regarding the need for repeat procedures, costs of complication management, total hospital stay and quality of life. Heterogeneity of hepatocellular carcinoma (HCC) patients as well as the shortcomings of clinical classifications, randomized clinical trials and cost-effectiveness studies make it difficult to choose between treatment alternatives in this field. As in other countries, these challenges lead to differences in treatment choice across different centers in Turkey. The present expert panel used two round modified Delphi method to investigate the resources and clinical parameters referenced while selecting patients for drug-eluting beads (DEB)-TACE and TARE treatment modalities in Turkish clinical practice. The cost-effectiveness parameters and comparisons of these treatments have also been evaluated at a prediction level. The panelists stated that they most commonly use the BCLC staging system for the management of HCC patients in Turkey. However, they did not find any of the staging systems or treatment guidelines sufficient enough for their clinical practice in terms of covering the down-staging intent of treatments. Since living donor transplant preference is higher in Turkey than the rest of the Western countries, down-staging treatments are thought to be more prioritized in Turkey than that in other Western countries. The panelists reached a consensus that TARE may provide improved OS and reduce the number of repeat procedures compared to DEB-TACE in intermediate-stage patients with a single tumor spanning a diameter above 5 cm who experience recurrence after previous treatment with TACE and most TACE-naïve patient groups in intermediate stage. Based on the consensus on OS and the number of procedures, the panelists assumed that TARE would be more cost-effective than DEB-TACE in most groups of TACE-naïve patients in intermediate stage and in those with a single tumor spanning a diameter above 5 cm. It was also stated that the predicted cost-effectiveness advantage of TARE could be more pronounced in patients with a tumor diameter greater than 7 cm.
- 19 November 2021
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 27 (6) , 732-739
The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey
Clinical studies conducted in different geographic regions using different methods to compare transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) have demonstrated discordant results. Meta-analyses in this field indicate comparable overall survival (OS) with TACE and TARE, while reporting a longer time to progression and a higher downstaging effect with TARE treatment. In terms of isolated procedure costs, treatment with TARE is 2 to 3 times more, and in some countries even more, expensive than TACE. However, relevant literature indicates that TARE is more advantageous compared to TACE regarding the need for repeat procedures, costs of complication management, total hospital stay and quality of life. Heterogeneity of hepatocellular carcinoma (HCC) patients as well as the shortcomings of clinical classifications, randomized clinical trials and cost-effectiveness studies make it difficult to choose between treatment alternatives in this field. As in other countries, these challenges lead to differences in treatment choice across different centers in Turkey. The present expert panel used two round modified Delphi method to investigate the resources and clinical parameters referenced while selecting patients for drug-eluting beads (DEB)-TACE and TARE treatment modalities in Turkish clinical practice. The cost-effectiveness parameters and comparisons of these treatments have also been evaluated at a prediction level. The panelists stated that they most commonly use the BCLC staging system for the management of HCC patients in Turkey. However, they did not find any of the staging systems or treatment guidelines sufficient enough for their clinical practice in terms of covering the down-staging intent of treatments. Since living donor transplant preference is higher in Turkey than the rest of the Western countries, down-staging treatments are thought to be more prioritized in Turkey than that in other Western countries. The panelists reached a consensus that TARE may provide improved OS and reduce the number of repeat procedures compared to DEB-TACE in intermediate-stage patients with a single tumor spanning a diameter above 5 cm who experience recurrence after previous treatment with TACE and most TACE-naïve patient groups in intermediate stage. Based on the consensus on OS and the number of procedures, the panelists assumed that TARE would be more cost-effective than DEB-TACE in most groups of TACE-naïve patients in intermediate stage and in those with a single tumor spanning a diameter above 5 cm. It was also stated that the predicted cost-effectiveness advantage of TARE could be more pronounced in patients with a tumor diameter greater than 7 cm.
- Open Access
- 31 May 2019
- Published by Suleyman Demirel Universitesi Fen Edebiyat Fakultesi Fen Dergisi in Süleyman Demirel Üniversitesi Fen Edebiyat Fakültesi Fen Dergisi
- Vol. 14 (1) , 39-56
SPECT – BT ’nin Kalite Kontrolleri
The one of the aim of nuclear medicine is diagnosis of an abnormal metabolic activities in target organs. In a routine nuclear medicine imaging procedure, a radiopharmaceutical is used. Radiopharmaceutical’s radionuclide part emits gamma radiation. This radiation is dedected by Gamma Camera or Single Photon Emission Computed Tomography (SPECT). A computed tomography (CT) device was added to the SPECT(SPECT- CT). To combine anatomical images. Image quality of this device is important for accurate diagnosis and treatment of diseases. By means of quality control tests, performance changes of device are dedected. A various quality control parameters such as uniformity, sensivity, resolution, linearity have been developed for Gamma cameras, SPECT. Quality control test results are should be verify by comparing acceptable results. In this study, quality control tests of SPECT-CT are performed as proposed by the National Electrical Manufacturers Association ( NEMA) and it was aimed to investigate some correction methods.
- 31 May 2019
- Published by Suleyman Demirel Universitesi Fen Edebiyat Fakultesi Fen Dergisi in Süleyman Demirel Üniversitesi Fen Edebiyat Fakültesi Fen Dergisi
- Vol. 14 (1) , 39-56
Open AccessSPECT – BT ’nin Kalite Kontrolleri
The one of the aim of nuclear medicine is diagnosis of an abnormal metabolic activities in target organs. In a routine nuclear medicine imaging procedure, a radiopharmaceutical is used. Radiopharmaceutical’s radionuclide part emits gamma radiation. This radiation is dedected by Gamma Camera or Single Photon Emission Computed Tomography (SPECT). A computed tomography (CT) device was added to the SPECT(SPECT- CT). To combine anatomical images. Image quality of this device is important for accurate diagnosis and treatment of diseases. By means of quality control tests, performance changes of device are dedected. A various quality control parameters such as uniformity, sensivity, resolution, linearity have been developed for Gamma cameras, SPECT. Quality control test results are should be verify by comparing acceptable results. In this study, quality control tests of SPECT-CT are performed as proposed by the National Electrical Manufacturers Association ( NEMA) and it was aimed to investigate some correction methods.
- Open Access
- 1 April 2011
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 20 (1) , 7-13
The Additional Value of Tc 99m HMPAO White Blood Cell SPECT in the Evaluation of Bone and Soft Tissue Infections
The aim of this prospective study was to evaluate the additional value of Tc 99m HMPAO white blood cell (WBC) SPECT for bone and soft tissue infections. Thirty-eight patients with suspected bone and joint infection were included in the study. Patients were assigned into 2 groups according to the presence of orthopedic implants. All patients had multiphase bone scan (BS) with Tc 99m methylene diphosphonate and WBC scintigraphy. The planar images of BS and WBC images were evaluated together. SPECT WBC images were evaluated separately. Group 1 had 30 patients including 12 patients with diabetic foot, 17 patients with suspected relapse of chronic osteomyelitis and 1 with septic arthritis. In 19 of 30 patients, BS and planar WBC images were similar with SPECT images in terms of final diagnosis. In the remaining 11 patients, planar BS+planar WBC images and SPECT WBC images were discordant. Group 2 included 8 patients with suspected infection of orthopedic implants. There was no difference between planar BS+planar WBC images and SPECT WBC in 6 of 8 patients. SPECT WBC images changed the diagnosis of 13 (34.2%) patients in the whole group. SPECT WBC images did not have any contribution in the evaluation of the 6 patients who had reactive changes. SPECT images made significant contribution in discriminating soft tissue infection from osteomyelitis and improved diagnosis in terms of localization and the extent of disease. None declared.
- 1 April 2011
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 20 (1) , 7-13
Open AccessThe Additional Value of Tc 99m HMPAO White Blood Cell SPECT in the Evaluation of Bone and Soft Tissue Infections
The aim of this prospective study was to evaluate the additional value of Tc 99m HMPAO white blood cell (WBC) SPECT for bone and soft tissue infections. Thirty-eight patients with suspected bone and joint infection were included in the study. Patients were assigned into 2 groups according to the presence of orthopedic implants. All patients had multiphase bone scan (BS) with Tc 99m methylene diphosphonate and WBC scintigraphy. The planar images of BS and WBC images were evaluated together. SPECT WBC images were evaluated separately. Group 1 had 30 patients including 12 patients with diabetic foot, 17 patients with suspected relapse of chronic osteomyelitis and 1 with septic arthritis. In 19 of 30 patients, BS and planar WBC images were similar with SPECT images in terms of final diagnosis. In the remaining 11 patients, planar BS+planar WBC images and SPECT WBC images were discordant. Group 2 included 8 patients with suspected infection of orthopedic implants. There was no difference between planar BS+planar WBC images and SPECT WBC in 6 of 8 patients. SPECT WBC images changed the diagnosis of 13 (34.2%) patients in the whole group. SPECT WBC images did not have any contribution in the evaluation of the 6 patients who had reactive changes. SPECT images made significant contribution in discriminating soft tissue infection from osteomyelitis and improved diagnosis in terms of localization and the extent of disease. None declared.
- 1 November 2002
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 29 (11) , 1433-1437
Is furosemide administration effective in improving the accuracy of determination of differential renal function by means of technetium-99m DMSA in patients with hydronephrosis
It has been suggested that determination of differential renal function (DRF)using technetium-99m dimercaptosuccinic acid (DMSA) may lead to overestimation of the function of an obstructed kidney in patients with excretion abnormalities owing to pelvic retention of DMSA. Recently published guidelines have recommended use of furosemide injection when calculating DRF in these particular patients. The aim of this study was to evaluate the effect of diuretic administration on the determination of DRF using DMSA scintigraphy. For this purpose, 19 patients, aged from 1 month to 69 years (19.4±24.8 years, 15 males, 4 females), in whom pelvic retention had been documented by diuresis scintigraphy were included in the study. DMSA scintigraphy was performed in all patients 2–4 h after injection and six planar images were obtained. Immediately after the standard study, furosemide was injected in all patients, and 30 min later the same number of images was obtained. DRF was calculated for each patient and from each DMSA study by using the arithmetic mean method. The difference between two studies (DMSA scintigraphy with or without furosemide administration and diuresis scintigraphy) was expressed as a percentage of the mean value of the two studies (the DRF value of the affected kidney was thus taken into account). The mean of the differences represented the systemic bias and the SD of the mean of the differences represented the precision of the technique. In seven patients, diuresis renography revealed an obstructive curve pattern. We did not observe any significant difference between the DRF values obtained before and after diuretic administration (P>0.5). When we compared DRF values obtained from standard and from diuretic DMSA studies, the mean of the differences was only 0.3% and the SD was only 1.2%. There was also no significant difference in DRF between patients with the obstructive curve pattern and those with a dilated renogram curve pattern (with washout of activity during the second phase of the study) (P>0.1). In conclusion, we did not observe interference from pelvicalyceal activity in patients with documented pelvic retention and infer that diuretic administration may be a useless intervention for improving the accuracy of determination of DRF.
- 1 November 2002
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 29 (11) , 1433-1437
Is furosemide administration effective in improving the accuracy of determination of differential renal function by means of technetium-99m DMSA in patients with hydronephrosis
It has been suggested that determination of differential renal function (DRF)using technetium-99m dimercaptosuccinic acid (DMSA) may lead to overestimation of the function of an obstructed kidney in patients with excretion abnormalities owing to pelvic retention of DMSA. Recently published guidelines have recommended use of furosemide injection when calculating DRF in these particular patients. The aim of this study was to evaluate the effect of diuretic administration on the determination of DRF using DMSA scintigraphy. For this purpose, 19 patients, aged from 1 month to 69 years (19.4±24.8 years, 15 males, 4 females), in whom pelvic retention had been documented by diuresis scintigraphy were included in the study. DMSA scintigraphy was performed in all patients 2–4 h after injection and six planar images were obtained. Immediately after the standard study, furosemide was injected in all patients, and 30 min later the same number of images was obtained. DRF was calculated for each patient and from each DMSA study by using the arithmetic mean method. The difference between two studies (DMSA scintigraphy with or without furosemide administration and diuresis scintigraphy) was expressed as a percentage of the mean value of the two studies (the DRF value of the affected kidney was thus taken into account). The mean of the differences represented the systemic bias and the SD of the mean of the differences represented the precision of the technique. In seven patients, diuresis renography revealed an obstructive curve pattern. We did not observe any significant difference between the DRF values obtained before and after diuretic administration (P>0.5). When we compared DRF values obtained from standard and from diuretic DMSA studies, the mean of the differences was only 0.3% and the SD was only 1.2%. There was also no significant difference in DRF between patients with the obstructive curve pattern and those with a dilated renogram curve pattern (with washout of activity during the second phase of the study) (P>0.1). In conclusion, we did not observe interference from pelvicalyceal activity in patients with documented pelvic retention and infer that diuretic administration may be a useless intervention for improving the accuracy of determination of DRF.